Associated tags: Suicide, Central Waqf Council, Psychiatry, Pharma, Psilocybin, Learned helplessness, Depression, Cancer, Anxiety, Patient, Coronavirus Scientific Advisory Board, Grammatical mood, Pharmaceutical industry, Novartis, CNS, Demoralization, Mood disorder, Mental health, ALS, Coronavirus Scientific Advisory Board (Turkey), Amyotrophic lateral sclerosis, FTD, Neurodegeneration
Locations: NEW YORK, US, NORTH AMERICA, SWITZERLAND, VEREINIGTE STAATEN VON AMERIKA, NY
Retrieved on:
Tuesday, November 7, 2023
FDA,
IND,
DSM-IV codes,
Food,
Safe,
Doctor of Philosophy,
Regulation of food and dietary supplements by the U.S. Food and Drug Administration,
CQD,
Interim,
Safety,
Depression,
Cancer,
Anxiety,
Patient,
Mental health,
Pharmaceutical industry This action by the FDA allows the Company to conduct a Phase 2b trial with RSTP1000 in patients with cancer and demoralization syndrome.
Key Points:
- This action by the FDA allows the Company to conduct a Phase 2b trial with RSTP1000 in patients with cancer and demoralization syndrome.
- The study is a multicenter, randomized, dose-ranging, double-blind, parallel-group study to investigate the preliminary efficacy, safety, and tolerability of a single dose of orally administered RSTP1000 for up to 6 months.
- These patients have more difficulties with adherence to cancer therapy and are also more likely to have suicidal thoughts.
- Oral psilocybin has shown promise as a novel, innovative treatment of demoralization in patients with cancer.1 2 3
Retrieved on:
Wednesday, November 1, 2023
FDA,
IND,
DSM-IV codes,
Food,
Safe,
Doctor of Philosophy,
Regulation of food and dietary supplements by the U.S. Food and Drug Administration,
CQD,
Interim,
Safety,
Depression,
Cancer,
Anxiety,
Patient,
Mental health,
Pharmaceutical industry This action by the FDA allows the Company to conduct a Phase 2b trial with RSTP1000 in patients with cancer and demoralization syndrome.
Key Points:
- This action by the FDA allows the Company to conduct a Phase 2b trial with RSTP1000 in patients with cancer and demoralization syndrome.
- The study is a multicenter, randomized, dose-ranging, double-blind, parallel-group study to investigate the preliminary efficacy, safety, and tolerability of a single dose of orally administered RSTP1000 for up to 6 months.
- These patients have more difficulties with adherence to cancer therapy and are also more likely to have suicidal thoughts.
- Oral psilocybin has shown promise as a novel, innovative treatment of demoralization in patients with cancer.1 2 3
Psilocybin,
Cancer,
Mood disorder,
Mental health,
Anxiety,
Commercial,
Biotechnology,
Innes,
Learned helplessness,
Research,
Addiction medicine,
Depression,
Orexo,
Series,
CNS,
Growth,
Patient,
Novartis,
Psychotherapy,
Demoralization,
Grammatical mood,
Chairperson,
Senior,
Pharmaceutical industry New York, NY, January 5, 2023 - Reset Pharmaceuticals, Inc. (Reset Pharma), a privately held biotechnology company focused on the development of innovative treatments to address mental health indications related to life-altering diseases, today announces that Innes Meldrum has been appointed President and Chief Executive Officer.
Key Points:
- New York, NY, January 5, 2023 - Reset Pharmaceuticals, Inc. (Reset Pharma), a privately held biotechnology company focused on the development of innovative treatments to address mental health indications related to life-altering diseases, today announces that Innes Meldrum has been appointed President and Chief Executive Officer.
- Innes Meldrum has nearly 30 years of global experience in the biotechnology and technology industries, having most recently served as Senior Vice President and Chief Commercial Officer for Otsuka Pharmaceuticals North America.
- “We are delighted to have Innes join Reset Pharma as CEO,” said Philip Taub, Chair of the Board.
- I warmly welcome Innes and look forward to working with him and the entire Reset Pharma team.
Retrieved on:
Thursday, January 5, 2023
Psilocybin,
Cancer,
Mood disorder,
Mental health,
Anxiety,
Commercial,
Biotechnology,
Innes,
Learned helplessness,
Research,
Addiction medicine,
Depression,
Orexo,
Series,
CNS,
Growth,
Patient,
Novartis,
Psychotherapy,
Demoralization,
Grammatical mood,
Chairperson,
Senior,
Pharmaceutical industry NEW YORK, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Reset Pharmaceuticals, Inc. (Reset Pharma), a privately held biotechnology company focused on the development of innovative treatments to address mental health indications related to life-altering diseases, today announces that Innes Meldrum has been appointed President and Chief Executive Officer.
Key Points:
- NEW YORK, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Reset Pharmaceuticals, Inc. (Reset Pharma), a privately held biotechnology company focused on the development of innovative treatments to address mental health indications related to life-altering diseases, today announces that Innes Meldrum has been appointed President and Chief Executive Officer.
- Innes Meldrum has nearly 30 years of global experience in the biotechnology and technology industries, having most recently served as Senior Vice President and Chief Commercial Officer for Otsuka Pharmaceuticals North America.
- “We are delighted to have Innes join Reset Pharma as CEO,” said Philip Taub, Chair of the Board.
- I warmly welcome Innes and look forward to working with him and the entire Reset Pharma team.
Retrieved on:
Thursday, November 3, 2022
Depression,
MBA,
Frontotemporal dementia,
Cancer,
CNS,
Board,
Learned helplessness,
Risk,
ALS,
Anxiety,
Novartis Gene Therapies,
Central Waqf Council,
Novartis,
Psilocybin,
Strategic planning,
Patient,
Neurodegeneration,
Mood disorder,
FTD,
Psychiatry,
Grammatical mood,
Forward-looking statement,
Amyotrophic lateral sclerosis,
Mental health,
Demoralization,
Suicide,
Coronavirus Scientific Advisory Board (Turkey),
Pharmaceutical industry,
Neuroscience Ms. Deschamps is a highly experienced pharmaceutical executive who has worked at Board and senior management levels with global responsibilities.
Key Points:
- Ms. Deschamps is a highly experienced pharmaceutical executive who has worked at Board and senior management levels with global responsibilities.
- Before this, she was Worldwide Business Head, Neuroscience at Novartis, where she was responsible for the development and commercialization of the neuroscience portfolio.
- She has been involved in more than a dozen successful product approvals and launches in many therapeutic areas, including in neuroscience.
- We are very happy to welcome Lisa to the Board, said Philip Taub, Chair of the Board of Reset Pharma.
Retrieved on:
Wednesday, November 2, 2022
Depression,
MBA,
Frontotemporal dementia,
Cancer,
CNS,
Board,
Learned helplessness,
GLOBE,
Risk,
ALS,
Anxiety,
Central Waqf Council,
Novartis Gene Therapies,
Novartis,
Psilocybin,
Strategic planning,
Patient,
Neurodegeneration,
Mood disorder,
FTD,
Psychiatry,
Grammatical mood,
Forward-looking statement,
Amyotrophic lateral sclerosis,
Mental health,
Demoralization,
Suicide,
Coronavirus Scientific Advisory Board (Turkey),
Pharmaceutical industry,
Neuroscience Ms. Deschamps is a highly experienced pharmaceutical executive who has worked at Board and senior management levels with global responsibilities.
Key Points:
- Ms. Deschamps is a highly experienced pharmaceutical executive who has worked at Board and senior management levels with global responsibilities.
- Before this, she was Worldwide Business Head, Neuroscience at Novartis, where she was responsible for the development and commercialization of the neuroscience portfolio.
- She has been involved in more than a dozen successful product approvals and launches in many therapeutic areas, including in neuroscience.
- We are very happy to welcome Lisa to the Board, said Philip Taub, Chair of the Board of Reset Pharma.
